No single parameter, including nodule size, satisfactorily identifies a subset of patients to be electively investigated by FNAC, although several may be useful in this regard.
Objective: To evaluate if a nodule with shape taller than wide (anteroposterior/transverse diameter ratio, A/TR1) is a good predictor of malignancy independent of the size. Methods: We retrospectively examined the cytological and histological results of 7455 nodules (5198 patients) referred for ultrasound-guided-fine needle aspiration cytology (US-FNAC) in our hospital from January 1991 to September 2004. Results: A suitable FNAC was obtained from 6135 nodules (4495 patients); 34.6% were less than 1 cm in diameter (small nodules, SN). A diagnosis of carcinoma was histologically confirmed in 284/349 suspicious lesions after FNAC. The size of carcinoma nodules was not significantly associated with the occurrence of extracapsular growth (large nodules (LN): 10.5%, SN: 4.9%, NS) and lymph node metastasis (LN: 23.6%, SN: 25.0%, NS). Malignant lesions showed microcalcifications more frequently than benign nodules (72.2 vs 28.7%; P!0.001; (odds ratio, OR(confidence intervals, CI)Z9.9(7.2-13.4)). Similarly, A/TR1 (76 vs 40%; P!0.001; OR(CI)Z8.6(5.5-13.1)), blurred margins (52.8 vs 18.8%; P!0.001; OR(CI)Z7.7(5.6-10.2)), solid hypo-echoic appearance (80.6 vs 52.4%; P!0.001; OR(CI)Z 3.2(2.2-4.3)) and intranodular vascular pattern (type 2) (61.6 vs 49.7%; P!0.001; OR(CI)Z 1.7(1.3-2.3)) were significantly more frequent in malignant than in benign nodules. Conclusions: Our data show that no single parameter, including nodule size, satisfactorily identifies a subset of patients to be electively investigated by FNAC. We concluded that A/TR1 with at least two of US features (microcalcification, blurred margins, hypo-echoic pattern) is today the best compromise between missing cancers and cost-benefit.
OBJECTIVETo assess the interplay between metformin treatment and thyroid function in type 2 diabetic patients.RESEARCH DESIGN AND METHODSThe acute and long-term effects of metformin on thyroid axis hormones were assessed in diabetic patients with primary hypothyroidism who were either untreated or treated with levothyroxine (L-T4), as well as in diabetic patients with normal thyroid function.RESULTSNo acute changes were found in 11 patients with treated hypothyroidism. After 1 year of metformin administration, a significant thyrotropin (TSH) decrease (P < 0.001) was observed in diabetic subjects with hypothyroidism who were either treated (n = 29; from 2.37 ± 1.17 to 1.41 ± 1.21 mIU/l) or untreated (n = 18; 4.5 ± 0.37 vs. 2.93 ± 1.48) with L-T4, but not in 54 euthyroid subjects. No significant change in free T4 (FT4) was observed in any group.CONCLUSIONSMetformin administration influences TSH without change of FT4 in patients with type 2 diabetes and concomitant hypothyroidism. The need for reevaluation of thyroid function in these patients within 6–12 months after starting metformin is indicated.
We suggest always performing a total thyroidectomy followed by radiometabolic therapy in papillary carcinomas independent of their size. If the choice in PMCs should be more conservative (hemithyroidectomy), we purpose to limit this procedure to the cancers without Doppler features suggesting intranodular vascular pattern.
Objective: A retrospective study to evaluate the changes in TSH concentrations in diabetic patients treated or not treated with metformin and/or L-thyroxine (L-T 4 ). Methods: Three hundred and ninety three euthyroid diabetic patients were divided into three groups on the basis of metformin and/or L-T 4 treatment: Group (MK/LK), 119 subjects never treated with metformin and L-T 4 ; Group (MC/LK), 203 subjects who started metformin treatment at recruitment; and Group (MC/LC), 71 patients on L-T 4 who started metformin recruitment. Results: The effect of metformin on serum TSH concentrations was analyzed in relation to the basal value of TSH (below 2.5 mIU/l (Q1) or between 2.51 and 4.5 mIU/l (Q2)). In patients of group MC/LC, TSH significantly decreased independently from the basal level (Q1, from 1.45G0.53 to 1.01G1.12 mU/l (PZ0.037); Q2, from 3.60G0.53 to 1.91G0.89 mU/l (P!0.0001)). In MC/LK group, the decrease in TSH was significant only in those patients with a basal high-normal serum TSH (Q2: from 3.24G0.51 to 2.27G1.28 mU/l (PZ0.004)); in MK/LK patients, no significant changes in TSH levels were observed.In patients of group MC/LK showing high-normal basal TSH levels, a significant decrease in TSH was observed independently from the presence or absence of thyroid peroxidase antibodies (AbTPO; Q2 AbTPO C: from 3.38G0.48 to 1.87G1.08 mU/l (P!0.001); Q2 AbTPO K: from 3.21G 0.52 to 2.34G1.31 mU/l (P!0.001)). Conclusions: These data strengthen the known TSH-lowering effect of metformin in diabetic patients on L-T 4 treatment and shows a significant reduction of TSH also in euthyroid patients with higher baseline TSH levels independently from the presence of AbTPO.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.